BioNTech's Founding Duo Will Leave to Start New mRNA Firm [Yahoo! Finance]
ASTELLAS PHARMA UNSP/ADR (ALPMY)
NASDAQ:AMEX Investor Relations:
astellas.com/jp/en/investors
Company Research
Source: Yahoo! Finance
biotech focused on messenger RNA, the technology behind their blockbuster Covid-19 vaccine. The couple, Ugur Sahin and Özlem Türeci, will shift to the new company by the end of the year, BioNTech said Tuesday. The firm's American depositary receipts plunged as much as 21% in pre-market trading. Most Read from Bloomberg Trump Signals Possible End to War, Floats Removing Oil Sanctions Greek Oil Tanker Exits Strait of Hormuz With Its Signal Off Stocks Climb as Trump Hints War Could Be Over Soon: Markets Wrap Timely Gold Bet Yields 1,994% Return for Billionaire Family US Planes Fly Out of Korea as Asset Redeployment Reports Grow “The departure of the company's founders is devastating news for the company and its shareholders” at a critical juncture, said Markus Manns, a portfolio manager at Union Investment and a BioNTech investor. “Both had been the heart and brain of the business.” Sahin and Türeci, who are married, are scientists who'd rather devote their energy to pu
Show less
Read more
Impact Snapshot
Event Time:
ALPMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALPMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALPMY alerts
High impacting ASTELLAS PHARMA UNSP/ADR news events
Weekly update
A roundup of the hottest topics
ALPMY
News
- Astellas Pharma (ALPMY) was upgraded by Jefferies Financial Group Inc. from "hold" to "strong-buy".MarketBeat
- IsomAb appoints Dr Philip Brainin as Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
- JAMP Pharma Group Expands Oncology Portfolio with PrJAMP Enzalutamide [Yahoo! Finance]Yahoo! Finance
- BioNTech's Founding Duo Will Leave to Start New mRNA Firm [Yahoo! Finance Canada]Yahoo! Finance Canada
- Will Linzess Continue to Aid IRWD's Top Line in 2026 After a Soft Q4? [Yahoo! Finance]Yahoo! Finance